Episode 42: Establishing a New Drug Therapy

October 17, 2019
Christen Harm|Elaine Quilici

Pharmaceutical Executive

Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.

Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.